Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 DDI with Paroxetine and Duloxetine in Healthy Subjects
NCT02174822Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deudextromethorphan in Alzheimer's disease (AD) (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Change in plasma concentrations of paroxetine at 20 days, Change in plasma concentration of AVP-786 (parent and metabolites) at 20 days and 2 more. Started Jan 2014; status: completed.
02
Drugs
deudextromethorphan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02174822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174822.